Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says

Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.

Will Republican Focus On US Government Spending Cuts Hamper IRA Fixes? • Source: Shutterstock

Efforts to amend the Inflation Reduction Act to narrow the types of drugs subject to the law’s Medicare price negotiation program may have trouble succeeding in a political environment that will be increasingly focused on cutting spending, according to former Trump Administration official Joe Grogan.

Key Takeaways

  • Legislative relief from Medicare negotiation for small molecule and orphan drugs may be increasingly challenging.

Grogan, who served as director of the White House Domestic Policy Council and associate director for health programs at the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet